A Single-dose, Open-label, Parallel-group, Matched Trial Evaluating the Pharmacokinetics of Oral OPC-34712 Tablets in Subjects With Normal Renal Function and Renally Impaired Subjects.
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2015
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Attention-deficit hyperactivity disorder; Major depressive disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 11 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jan 2012 Actual patients number (19) added as reported by ClinicalTrials.gov.
- 11 Jan 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.